[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-001", "question": "A 45-year-old man with a history of migraine presents with acute onset of right-sided hemiparesis and aphasia. MRI shows restricted diffusion in the left middle cerebral artery territory, but no large vessel occlusion on angiography. Lumbar puncture reveals normal opening pressure, 5 WBCs/μL (all lymphocytes), protein 45 mg/dL, glucose 60 mg/dL, and negative oligoclonal bands. Serum testing is positive for anti-NMDA receptor antibodies. What is the most appropriate next step in management?", "options": ["Initiate intravenous thrombolysis", "Administer high-dose intravenous methylprednisolone", "Start rituximab infusion", "Perform plasmapheresis", "Administer acyclovir empirically"], "answer": "C", "answer_index": 2, "explanation": "The presentation suggests anti-NMDA receptor encephalitis mimicking stroke, and rituximab is indicated for refractory cases or as first-line in severe presentations per subspecialty guidelines. High-dose steroids are often initial, but in antibody-positive cases with stroke-like features, rituximab targets B-cell depletion more effectively. Plasmapheresis is an alternative but not superior in this context without evidence of fulminant progression.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (miskeyed)\\nVerdict on keyed answer: Miskeyed – C is not the best answer\\nKey stem clues: Acute focal deficit (right hemiparesis, aphasia) with DWI-restricted infarct in left MCA territory and no large-vessel occlusion; CSF essentially normal; serum anti–NMDA receptor antibodies positive. The imaging is classic for acute ischemic stroke, not encephalitis (which typically shows normal MRI or limbic/temporal changes, psychiatric symptoms, seizures, dyskinesias). Anti-NMDA receptor positivity alone, absent compatible syndrome, should not override clear infarct on MRI.\\nLogical/medical issues: The rationale reinterprets the case as anti-NMDA receptor encephalitis “mimicking stroke,” but the provided data (territorial infarct) contradict that diagnosis. For confirmed or strongly suspected anti-NMDA receptor encephalitis, first-line therapy is high‑dose IV steroids ± IVIG or plasmapheresis; rituximab is second-line for refractory disease. Thus choice B (high‑dose IV methylprednisolone) is the only reasonable immunotherapy option and better supported than rituximab.\\nMinimal fix: Either (1) change the MRI description to something compatible with encephalitis (e.g., normal or limbic changes) and specify failure of steroids to justify C, or (2) change the keyed answer to B to align with current standard first‑line treatment.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (miskeyed)\nVerdict on keyed answer: Miskeyed – C is not the best answer\nKey stem clues: Acute focal deficit (right hemiparesis, aphasia) with DWI-restricted infarct in left MCA territory and no large-vessel occlusion; CSF essentially normal; serum anti–NMDA receptor antibodies positive. The imaging is classic for acute ischemic stroke, not encephalitis (which typically shows normal MRI or limbic/temporal changes, psychiatric symptoms, seizures, dyskinesias). Anti-NMDA receptor positivity alone, absent compatible syndrome, should not override clear infarct on MRI.\nLogical/medical issues: The rationale reinterprets the case as anti-NMDA receptor encephalitis “mimicking stroke,” but the provided data (territorial infarct) contradict that diagnosis. For confirmed or strongly suspected anti-NMDA receptor encephalitis, first-line therapy is high‑dose IV steroids ± IVIG or plasmapheresis; rituximab is second-line for refractory disease. Thus choice B (high‑dose IV methylprednisolone) is the only reasonable immunotherapy option and better supported than rituximab.\nMinimal fix: Either (1) change the MRI description to something compatible with encephalitis (e.g., normal or limbic changes) and specify failure of steroids to justify C, or (2) change the keyed answer to B to align with current standard first‑line treatment.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-002", "question": "A 62-year-old woman with Parkinson's disease on levodopa/carbidopa develops sudden visual hallucinations and paranoia. She has no fever, normal vital signs, and her Unified Parkinson's Disease Rating Scale score has worsened by 15 points. CSF analysis shows 10 WBCs/μL (mononuclear), protein 55 mg/dL, and negative PCR for herpes simplex virus. What is the most likely underlying mechanism?", "options": ["Dopaminergic overstimulation in mesolimbic pathways", "Alpha-synuclein aggregation in occipital lobes", "Autoimmune encephalitis with anti-LGI1 antibodies", "Lewy body deposition in limbic structures", "Serotonergic imbalance from medication withdrawal"], "answer": "C", "answer_index": 2, "explanation": "This scenario points to anti-LGI1 encephalitis, which can mimic psychiatric decompensation in Parkinson's patients and is associated with faciobrachial dystonic seizures or hallucinations. Dopaminergic effects are common but do not explain the CSF pleocytosis. Lewy body involvement is typical in dementia with Lewy bodies but lacks the acute inflammatory CSF findings here.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (primary), possibly N/M secondary.\\nVerdict on keyed answer: Miskeyed. The keyed answer C (anti-LGI1 autoimmune encephalitis) is not well supported and conflicts with the vignette focus and options.\\nKey stem clues: Known Parkinson’s disease on levodopa/carbidopa; sudden onset visual hallucinations and paranoia; no systemic signs; mild CSF lymphocytic pleocytosis and mild protein elevation; negative HSV PCR; worsening UPDRS. The question asks for the most likely underlying mechanism of this presentation.\\nThe most straightforward, board-style interpretation is dopaminergic overstimulation in mesolimbic pathways (A), a classic cause of hallucinations in patients on levodopa. Mild CSF abnormalities (10 WBC/µL, protein 55) are nonspecific and do not strongly implicate autoimmune encephalitis; anti-LGI1 encephalitis typically has more complex presentations (seizures, hyponatremia), which are not given here. D (Lewy body deposition) explains chronic dementia with hallucinations, not acute change with medication. B is speculative and unstandard, and E is irrelevant (no serotonergic drug context).\\nMain medical accuracy issue: the explanation overinterprets minor CSF changes to favor anti-LGI1, which is not the most likely mechanism.\\nMinimal fix: Change the correct answer key to A and adjust the explanation accordingly to emphasize dopaminergic mesolimbic overstimulation as the cause of hallucinations.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (primary), possibly N/M secondary.\nVerdict on keyed answer: Miskeyed. The keyed answer C (anti-LGI1 autoimmune encephalitis) is not well supported and conflicts with the vignette focus and options.\nKey stem clues: Known Parkinson’s disease on levodopa/carbidopa; sudden onset visual hallucinations and paranoia; no systemic signs; mild CSF lymphocytic pleocytosis and mild protein elevation; negative HSV PCR; worsening UPDRS. The question asks for the most likely underlying mechanism of this presentation.\nThe most straightforward, board-style interpretation is dopaminergic overstimulation in mesolimbic pathways (A), a classic cause of hallucinations in patients on levodopa. Mild CSF abnormalities (10 WBC/µL, protein 55) are nonspecific and do not strongly implicate autoimmune encephalitis; anti-LGI1 encephalitis typically has more complex presentations (seizures, hyponatremia), which are not given here. D (Lewy body deposition) explains chronic dementia with hallucinations, not acute change with medication. B is speculative and unstandard, and E is irrelevant (no serotonergic drug context).\nMain medical accuracy issue: the explanation overinterprets minor CSF changes to favor anti-LGI1, which is not the most likely mechanism.\nMinimal fix: Change the correct answer key to A and adjust the explanation accordingly to emphasize dopaminergic mesolimbic overstimulation as the cause of hallucinations.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-003", "question": "A 28-year-old woman at 32 weeks gestation presents with severe pelvic pain and vaginal bleeding. Ultrasound shows a low-lying placenta with abnormal lacunae and loss of the retroplacental clear space. MRI confirms myometrial thinning and turbulent flow voids. What is the most appropriate management strategy?", "options": ["Expectant management with bed rest", "Immediate cesarean delivery", "Uterine artery embolization", "Balloon tamponade post-delivery", "Prophylactic internal iliac artery ligation"], "answer": "E", "answer_index": 4, "explanation": "This describes placenta accreta spectrum, and prophylactic internal iliac artery ligation reduces hemorrhage risk during planned cesarean hysterectomy in high-risk cases. Immediate delivery risks uncontrolled bleeding without preparation. Embolization is adjunctive but not primary in antenatal planning for accreta.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U/K (underspecified and likely miskeyed)\\nVerdict on keyed answer: Not uniquely determinable; keyed answer is likely incorrect as “single best.”\\n\\nKey stem clues: 32 weeks, severe pelvic pain, vaginal bleeding, low-lying placenta with lacunae and loss of retroplacental clear space, MRI with myometrial thinning and flow voids → placenta accreta spectrum (likely increta/percreta) with symptomatic bleeding, preterm.\\n\\nThe core issue is management at 32 weeks with active bleeding vs long‑term surgical planning. Standard care for stable placenta accreta is planned cesarean (often with hysterectomy) around 34–36 weeks at a tertiary center; prophylactic internal iliac ligation is not an established routine antenatal “most appropriate management.” The stem does not clarify hemodynamic stability, desire for fertility, or timing of planned delivery, making it unclear whether immediate delivery vs stabilization and transfer vs procedural adjuncts is intended. None of the options explicitly state “planned cesarean hysterectomy at 34–36 weeks,” so the actual best practice is absent. Thus no option is clearly best, and privileging option E is weakly supported and somewhat outdated/controversial.\\n\\nMinimal fix: Rewrite the stem to describe a hemodynamically stable patient being scheduled for delivery and include an option like “Planned cesarean hysterectomy at 34–36 weeks at a tertiary care center.”\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U/K (underspecified and likely miskeyed)\nVerdict on keyed answer: Not uniquely determinable; keyed answer is likely incorrect as “single best.”\n\nKey stem clues: 32 weeks, severe pelvic pain, vaginal bleeding, low-lying placenta with lacunae and loss of retroplacental clear space, MRI with myometrial thinning and flow voids → placenta accreta spectrum (likely increta/percreta) with symptomatic bleeding, preterm.\n\nThe core issue is management at 32 weeks with active bleeding vs long‑term surgical planning. Standard care for stable placenta accreta is planned cesarean (often with hysterectomy) around 34–36 weeks at a tertiary center; prophylactic internal iliac ligation is not an established routine antenatal “most appropriate management.” The stem does not clarify hemodynamic stability, desire for fertility, or timing of planned delivery, making it unclear whether immediate delivery vs stabilization and transfer vs procedural adjuncts is intended. None of the options explicitly state “planned cesarean hysterectomy at 34–36 weeks,” so the actual best practice is absent. Thus no option is clearly best, and privileging option E is weakly supported and somewhat outdated/controversial.\n\nMinimal fix: Rewrite the stem to describe a hemodynamically stable patient being scheduled for delivery and include an option like “Planned cesarean hysterectomy at 34–36 weeks at a tertiary care center.”", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-004", "question": "A 35-year-old woman with endometriosis undergoes laparoscopic excision and develops postoperative fever, leukocytosis, and pelvic pain. CT shows a 5 cm complex adnexal mass with gas bubbles. Blood cultures are negative, but vaginal cultures grow mixed anaerobes. What is the most likely diagnosis?", "options": ["Ovarian abscess from bowel perforation", "Endometrioma superinfection", "Tubo-ovarian abscess from pelvic inflammatory disease", "Postoperative hematoma with secondary infection", "Clostridial myonecrosis of the uterus"], "answer": "A", "answer_index": 0, "explanation": "Bowel perforation during endometriosis surgery can lead to ovarian abscess with gas-forming anaerobes, explaining the imaging and cultures. Endometrioma infection is less likely without prior instrumentation. Tubo-ovarian abscess typically involves gonadal pathogens, not mixed anaerobes from bowel flora.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (multiple defensible answers) with possible K (miskey).\\nVerdict on keyed answer: Not uniquely determinable; A is arguable but D is also well-defensible.\\n\\nKey stem clues: Recent laparoscopic excision for endometriosis; postoperative fever, leukocytosis, pelvic pain; CT: 5 cm complex adnexal mass with gas bubbles; negative blood cultures; vaginal cultures with mixed anaerobes (bowel-type flora). No explicit mention of recognized bowel perforation, free intraperitoneal air, or direct bowel content spillage to ovary.\\n\\nOption A (ovarian abscess from bowel perforation) requires assuming a perforation communicated directly with the ovary; this is not stated. Option D (postoperative hematoma with secondary infection) also explains a complex adnexal mass with gas from anaerobic infection in the operative field and is a well-known postoperative complication; it is at least as plausible. Distinguishing features between ovarian vs. postoperative infected collection are not provided.\\n\\nMedical accuracy: The pathophysiology of anaerobic abscess from bowel flora after pelvic surgery is correct; TOA from PID is less likely; clostridial myonecrosis and isolated endometrioma superinfection are less typical. Main issue is lack of discriminating detail between A and D.\\n\\nMinimal fix: Add explicit evidence of bowel perforation with ovarian involvement or, alternatively, remove option D or specify imaging suggesting ovarian origin rather than postoperative collection.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple defensible answers) with possible K (miskey).\nVerdict on keyed answer: Not uniquely determinable; A is arguable but D is also well-defensible.\n\nKey stem clues: Recent laparoscopic excision for endometriosis; postoperative fever, leukocytosis, pelvic pain; CT: 5 cm complex adnexal mass with gas bubbles; negative blood cultures; vaginal cultures with mixed anaerobes (bowel-type flora). No explicit mention of recognized bowel perforation, free intraperitoneal air, or direct bowel content spillage to ovary.\n\nOption A (ovarian abscess from bowel perforation) requires assuming a perforation communicated directly with the ovary; this is not stated. Option D (postoperative hematoma with secondary infection) also explains a complex adnexal mass with gas from anaerobic infection in the operative field and is a well-known postoperative complication; it is at least as plausible. Distinguishing features between ovarian vs. postoperative infected collection are not provided.\n\nMedical accuracy: The pathophysiology of anaerobic abscess from bowel flora after pelvic surgery is correct; TOA from PID is less likely; clostridial myonecrosis and isolated endometrioma superinfection are less typical. Main issue is lack of discriminating detail between A and D.\n\nMinimal fix: Add explicit evidence of bowel perforation with ovarian involvement or, alternatively, remove option D or specify imaging suggesting ovarian origin rather than postoperative collection.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-005", "question": "A 58-year-old man with hypertrophic cardiomyopathy presents with syncope. Echocardiogram shows left ventricular outflow tract gradient of 80 mmHg at rest, increasing to 120 mmHg with Valsalva. He is on beta-blockers but remains symptomatic. Genetic testing reveals a MYH7 mutation. What is the most appropriate next intervention?", "options": ["Alcohol septal ablation", "Surgical myectomy", "Implantable cardioverter-defibrillator placement", "Dual-chamber pacing", "Mavacamten therapy"], "answer": "E", "answer_index": 4, "explanation": "Mavacamten, a cardiac myosin inhibitor, is indicated for symptomatic obstructive hypertrophic cardiomyopathy refractory to beta-blockers, targeting the underlying MYH7-related hypercontractility. Alcohol ablation and myectomy are invasive options for severe cases, but mavacamten offers medical management first. ICD is for arrhythmia risk, not outflow obstruction.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible)\\nVerdict on keyed answer: Not uniquely determinable; E is defensible but so is B (and arguably A)\\nKey stem clues: Symptomatic obstructive HCM (resting LVOT gradient 80 mmHg, 120 mmHg with Valsalva) despite beta‑blockers; age 58; MYH7 mutation confirms sarcomeric HCM but doesn’t change standard invasive vs medical sequencing.\\nMain logical issues: Contemporary guidelines (2020 AHA/ACC; 2023 ESC) recommend for symptomatic obstructive HCM refractory to maximally tolerated medical therapy: septal reduction therapy (surgical myectomy or alcohol septal ablation) as class I, while mavacamten has emerged as an option but is not yet clearly mandated as the single next step ahead of established septal reduction, especially in a patient with clear, severe, fixed obstruction. The stem omits key decision‑making data (NYHA class, comorbidities, center expertise, blood pressure, arrhythmia history) needed to choose definitively between advanced medical therapy vs SRT. Thus both mavacamten (E) and surgical myectomy (B) are reasonable “most appropriate next intervention,” making the item non‑discriminating.\\nMain medical accuracy issues: Overstates mavacamten as preferred before invasive therapy in all such patients; guideline nuance is ignored.\\nMinimal fix: Specify guideline context and that patient prefers to avoid surgery and meets criteria for initiation of mavacamten, or else change key to a septal reduction option and clarify maximal tolerated therapy including disopyramide/verapamil has been tried.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible)\nVerdict on keyed answer: Not uniquely determinable; E is defensible but so is B (and arguably A)\nKey stem clues: Symptomatic obstructive HCM (resting LVOT gradient 80 mmHg, 120 mmHg with Valsalva) despite beta‑blockers; age 58; MYH7 mutation confirms sarcomeric HCM but doesn’t change standard invasive vs medical sequencing.\nMain logical issues: Contemporary guidelines (2020 AHA/ACC; 2023 ESC) recommend for symptomatic obstructive HCM refractory to maximally tolerated medical therapy: septal reduction therapy (surgical myectomy or alcohol septal ablation) as class I, while mavacamten has emerged as an option but is not yet clearly mandated as the single next step ahead of established septal reduction, especially in a patient with clear, severe, fixed obstruction. The stem omits key decision‑making data (NYHA class, comorbidities, center expertise, blood pressure, arrhythmia history) needed to choose definitively between advanced medical therapy vs SRT. Thus both mavacamten (E) and surgical myectomy (B) are reasonable “most appropriate next intervention,” making the item non‑discriminating.\nMain medical accuracy issues: Overstates mavacamten as preferred before invasive therapy in all such patients; guideline nuance is ignored.\nMinimal fix: Specify guideline context and that patient prefers to avoid surgery and meets criteria for initiation of mavacamten, or else change key to a septal reduction option and clarify maximal tolerated therapy including disopyramide/verapamil has been tried.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-006", "question": "A 70-year-old woman with atrial fibrillation on apixaban develops acute chest pain. Coronary angiography shows spontaneous coronary artery dissection in the left anterior descending artery. She is hemodynamically stable with TIMI 3 flow. What is the most appropriate management?", "options": ["Percutaneous coronary intervention with stenting", "Continuation of apixaban with close monitoring", "Switch to dual antiplatelet therapy", "Surgical bypass grafting", "Conservative management with beta-blockers"], "answer": "E", "answer_index": 4, "explanation": "Conservative management with beta-blockers is preferred for stable spontaneous coronary artery dissection with preserved flow, as it promotes healing and reduces shear stress. Anticoagulation like apixaban increases bleeding risk in dissection. PCI is reserved for unstable cases due to high complication rates.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 70-year-old woman, atrial fibrillation on apixaban, acute chest pain; angiography shows spontaneous coronary artery dissection (SCAD) in LAD; patient is hemodynamically stable with TIMI 3 flow (normal distal perfusion). In contemporary practice, stable SCAD with preserved flow is generally managed conservatively with medical therapy (especially beta-blockers to reduce shear stress), as most lesions heal spontaneously and PCI has higher failure/complication rates in SCAD.\\nOption E, “Conservative management with beta-blockers,” aligns with this standard, assuming cessation/reevaluation of anticoagulation in the context of SCAD unless there is an overriding indication and after weighing stroke vs bleeding risk. Options A and D (PCI or CABG) are reserved for unstable patients, ongoing ischemia, left main, or compromised flow. B (continue apixaban) and C (switch to DAPT) ignore the bleeding/dissection propagation concerns and do not address the preferred beta-blocker–based conservative strategy.\\nMain medical accuracy issue: Minor nuance that anticoagulation management in AF with SCAD is individualized; blanket statement that anticoagulation “increases bleeding risk in dissection” is simplistic but directionally reasonable for an exam. \\nMinimal fix: Clarify in the stem that there is no ongoing ischemia and distal flow is preserved to emphasize conservative management.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 70-year-old woman, atrial fibrillation on apixaban, acute chest pain; angiography shows spontaneous coronary artery dissection (SCAD) in LAD; patient is hemodynamically stable with TIMI 3 flow (normal distal perfusion). In contemporary practice, stable SCAD with preserved flow is generally managed conservatively with medical therapy (especially beta-blockers to reduce shear stress), as most lesions heal spontaneously and PCI has higher failure/complication rates in SCAD.\nOption E, “Conservative management with beta-blockers,” aligns with this standard, assuming cessation/reevaluation of anticoagulation in the context of SCAD unless there is an overriding indication and after weighing stroke vs bleeding risk. Options A and D (PCI or CABG) are reserved for unstable patients, ongoing ischemia, left main, or compromised flow. B (continue apixaban) and C (switch to DAPT) ignore the bleeding/dissection propagation concerns and do not address the preferred beta-blocker–based conservative strategy.\nMain medical accuracy issue: Minor nuance that anticoagulation management in AF with SCAD is individualized; blanket statement that anticoagulation “increases bleeding risk in dissection” is simplistic but directionally reasonable for an exam. \nMinimal fix: Clarify in the stem that there is no ongoing ischemia and distal flow is preserved to emphasize conservative management.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-007", "question": "A 40-year-old man returning from West Africa presents with fever, myalgias, and petechial rash. Labs show thrombocytopenia, elevated liver enzymes, and PCR positive for Lassa virus. He develops acute kidney injury with oliguria. What is the most appropriate therapeutic intervention?", "options": ["Intravenous ribavirin", "Supportive care with hemodialysis", "Convalescent plasma transfusion", "Favipiravir administration", "Monoclonal antibody therapy"], "answer": "A", "answer_index": 0, "explanation": "Intravenous ribavirin is the mainstay for Lassa fever, reducing mortality especially when initiated early, and it addresses viremia in cases with renal involvement. Supportive care is essential but not sufficient alone. Favipiravir is investigational and not standard for Lassa.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible)\\nVerdict on keyed answer: Not uniquely determinable (A is strongly defensible but B also defensible as “most appropriate” given AKI with oliguria)\\n\\nKey stem clues: Confirmed Lassa virus infection; severe disease features—petechial rash, thrombocytopenia, elevated LFTs, and especially acute kidney injury with oliguria. Question asks for “most appropriate therapeutic intervention,” not specifically antiviral or mortality-reducing therapy.\\n\\nAnalysis: For Lassa fever, IV ribavirin is widely accepted as the specific antiviral treatment that reduces mortality, particularly when started early, so A is medically appropriate. However, the stem emphasizes acute kidney injury with oliguria, and option B (“supportive care with hemodialysis”) describes a life-saving, specific intervention for the current complication. In real practice, both ribavirin and intensive supportive care (including dialysis) are standard; the question does not clearly prioritize antiviral management over organ support or specify timing (e.g., early vs late presentation). Thus a well-trained examinee could reasonably choose either A or B as “most appropriate,” creating ambiguity.\\n\\nMedical accuracy: Overall content is accurate; ribavirin is standard, favipiravir and monoclonals are not. No dangerous misinformation.\\n\\nMinimal fix: Modify the stem to ask for “the most appropriate antiviral therapy” or remove B/rename it to generic “supportive care only” so A is uniquely best.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible)\nVerdict on keyed answer: Not uniquely determinable (A is strongly defensible but B also defensible as “most appropriate” given AKI with oliguria)\n\nKey stem clues: Confirmed Lassa virus infection; severe disease features—petechial rash, thrombocytopenia, elevated LFTs, and especially acute kidney injury with oliguria. Question asks for “most appropriate therapeutic intervention,” not specifically antiviral or mortality-reducing therapy.\n\nAnalysis: For Lassa fever, IV ribavirin is widely accepted as the specific antiviral treatment that reduces mortality, particularly when started early, so A is medically appropriate. However, the stem emphasizes acute kidney injury with oliguria, and option B (“supportive care with hemodialysis”) describes a life-saving, specific intervention for the current complication. In real practice, both ribavirin and intensive supportive care (including dialysis) are standard; the question does not clearly prioritize antiviral management over organ support or specify timing (e.g., early vs late presentation). Thus a well-trained examinee could reasonably choose either A or B as “most appropriate,” creating ambiguity.\n\nMedical accuracy: Overall content is accurate; ribavirin is standard, favipiravir and monoclonals are not. No dangerous misinformation.\n\nMinimal fix: Modify the stem to ask for “the most appropriate antiviral therapy” or remove B/rename it to generic “supportive care only” so A is uniquely best.\n", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-008", "question": "A 55-year-old immunocompromised patient with lung transplant develops dyspnea and ground-glass opacities on CT. Bronchoalveolar lavage PCR is positive for Pneumocystis jirovecii, but serum beta-D-glucan is negative. He is on trimethoprim-sulfamethoxazole prophylaxis. What explains the breakthrough infection?", "options": ["Dihydropteroate synthase gene mutation", "Non-adherence to prophylaxis", "Concurrent cytomegalovirus co-infection", "Inadequate dosing in obesity", "Atovaquone cross-resistance"], "answer": "A", "answer_index": 0, "explanation": "Mutations in the dihydropteroate synthase gene confer resistance to sulfamethoxazole in Pneumocystis, leading to breakthrough despite prophylaxis in immunocompromised hosts. Non-adherence is common but less likely with negative beta-D-glucan suggesting low burden. CMV co-infection exacerbates but does not cause resistance.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Immunocompromised solid-organ transplant recipient; on TMP-SMX prophylaxis; develops dyspnea and ground-glass opacities; BAL PCR positive for Pneumocystis jirovecii; serum β-D-glucan negative; question asks what explains a breakthrough infection. Among options, dihydropteroate synthase (DHPS) gene mutation is the only one that directly confers sulfonamide resistance in Pneumocystis, fitting a true “breakthrough despite prophylaxis.” Non-adherence would simply mean absence of effective prophylaxis, not a pharmacologic breakthrough; no evidence is given for this. CMV co-infection can worsen disease but not resistance. Inadequate dosing in obesity is theoretically possible but less specific, not indicated by the stem, and standard prophylaxis dosing is typically weight-based only at extremes. Atovaquone cross-resistance is irrelevant because the patient is on TMP-SMX, and such cross-resistance is not well-established for Pneumocystis.\\nMain logical issues: Minor—negative β-D-glucan is unusual but can occur with low-burden or localized disease; it does not undermine the resistance explanation. \\nMain medical accuracy issues: None major; item reflects known mechanism of sulfa resistance in Pneumocystis.\\nMinimal fix: Add a line indicating good adherence and appropriate TMP-SMX dosing to further exclude options B and D explicitly.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Immunocompromised solid-organ transplant recipient; on TMP-SMX prophylaxis; develops dyspnea and ground-glass opacities; BAL PCR positive for Pneumocystis jirovecii; serum β-D-glucan negative; question asks what explains a breakthrough infection. Among options, dihydropteroate synthase (DHPS) gene mutation is the only one that directly confers sulfonamide resistance in Pneumocystis, fitting a true “breakthrough despite prophylaxis.” Non-adherence would simply mean absence of effective prophylaxis, not a pharmacologic breakthrough; no evidence is given for this. CMV co-infection can worsen disease but not resistance. Inadequate dosing in obesity is theoretically possible but less specific, not indicated by the stem, and standard prophylaxis dosing is typically weight-based only at extremes. Atovaquone cross-resistance is irrelevant because the patient is on TMP-SMX, and such cross-resistance is not well-established for Pneumocystis.\nMain logical issues: Minor—negative β-D-glucan is unusual but can occur with low-burden or localized disease; it does not undermine the resistance explanation. \nMain medical accuracy issues: None major; item reflects known mechanism of sulfa resistance in Pneumocystis.\nMinimal fix: Add a line indicating good adherence and appropriate TMP-SMX dosing to further exclude options B and D explicitly.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-009", "question": "A 50-year-old woman with rheumatoid arthritis on tofacitinib presents with symmetric polyarthritis flare, fever, and macular rash. Labs show pancytopenia, ferritin 10,000 ng/mL, triglycerides 400 mg/dL, and fibrinogen 100 mg/dL. Bone marrow biopsy reveals hemophagocytosis. What is the most appropriate initial treatment?", "options": ["High-dose glucocorticoids", "Cyclosporine A", "Anakinra", "Etoposide-based chemotherapy", "Intravenous immunoglobulin"], "answer": "C", "answer_index": 2, "explanation": "Anakinra, an IL-1 inhibitor, is effective for macrophage activation syndrome in rheumatoid arthritis, targeting cytokine storm and improving survival without broad immunosuppression. Glucocorticoids are adjunctive but insufficient alone in JAK inhibitor-associated cases. Etoposide is for refractory HLH but not first-line here.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible; also partially U). Verdict on keyed answer: Not uniquely determinable; C (anakinra) is defensible but so is A (high-dose glucocorticoids). \\n\\nKey stem clues: Adult woman with RA on tofacitinib, acute fever, rash, symmetric polyarthritis flare, pancytopenia, very high ferritin, hypertriglyceridemia, hypofibrinogenemia, and hemophagocytosis ⇒ secondary HLH/macrophage activation syndrome (MAS) in RA, likely drug-associated. Question asks for “most appropriate initial treatment.”\\n\\nLogical issues: In adult secondary HLH/MAS associated with rheumatologic disease, standard initial therapy is high‑dose systemic glucocorticoids; biologic cytokine blockade (anakinra) is increasingly used and can be first-line or added early, but practice/guidelines are heterogeneous. The stem does not state steroid failure or contraindication, nor that this is specifically “steroid‑refractory” or “IL‑1–driven” disease. Thus both A and C can be argued as appropriate initial therapy, and the assertion that glucocorticoids are “adjunctive but insufficient” in JAK‑inhibitor–associated cases is not firmly established consensus.\\n\\nMedical accuracy: Overall sound recognition of MAS/HLH and reasonable discussion of treatment hierarchy, but overstates evidence against steroids as first-line, creating ambiguity.\\n\\nMinimal fix: Specify “steroid-refractory MAS” or change the key/explanation to make high-dose glucocorticoids the correct initial treatment, with anakinra as add-on/next step.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible; also partially U). Verdict on keyed answer: Not uniquely determinable; C (anakinra) is defensible but so is A (high-dose glucocorticoids). \n\nKey stem clues: Adult woman with RA on tofacitinib, acute fever, rash, symmetric polyarthritis flare, pancytopenia, very high ferritin, hypertriglyceridemia, hypofibrinogenemia, and hemophagocytosis ⇒ secondary HLH/macrophage activation syndrome (MAS) in RA, likely drug-associated. Question asks for “most appropriate initial treatment.”\n\nLogical issues: In adult secondary HLH/MAS associated with rheumatologic disease, standard initial therapy is high‑dose systemic glucocorticoids; biologic cytokine blockade (anakinra) is increasingly used and can be first-line or added early, but practice/guidelines are heterogeneous. The stem does not state steroid failure or contraindication, nor that this is specifically “steroid‑refractory” or “IL‑1–driven” disease. Thus both A and C can be argued as appropriate initial therapy, and the assertion that glucocorticoids are “adjunctive but insufficient” in JAK‑inhibitor–associated cases is not firmly established consensus.\n\nMedical accuracy: Overall sound recognition of MAS/HLH and reasonable discussion of treatment hierarchy, but overstates evidence against steroids as first-line, creating ambiguity.\n\nMinimal fix: Specify “steroid-refractory MAS” or change the key/explanation to make high-dose glucocorticoids the correct initial treatment, with anakinra as add-on/next step.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-010", "question": "A 65-year-old man with giant cell arteritis on prednisone taper develops jaw claudication and vision loss. ESR is 80 mm/hr, and temporal artery biopsy is negative. CTA shows aortic arch involvement. What is the most appropriate escalation in therapy?", "options": ["Increase prednisone to 60 mg daily", "Add methotrexate", "Initiate tocilizumab", "Start cyclophosphamide", "Perform temporal artery ultrasound"], "answer": "C", "answer_index": 2, "explanation": "Tocilizumab, an IL-6 inhibitor, is indicated for refractory giant cell arteritis with large vessel involvement, reducing relapse and steroid requirements. High-dose prednisone is initial but inadequate for escalation in biopsy-negative cases. Methotrexate is steroid-sparing but less effective for vision-threatening disease.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Known giant cell arteritis; currently on prednisone taper; new jaw claudication and vision loss = active, vision-threatening relapse; ESR 80 mm/hr; negative temporal artery biopsy (does not rule out GCA); CTA with aortic arch involvement = large-vessel GCA; question asks for escalation of therapy.\\nTocilizumab is guideline-supported for refractory/relapsing and/or large-vessel GCA and is superior to methotrexate as a steroid-sparing agent. Among options, it is the best escalation beyond glucocorticoids.\\nMain logical issue(s): The question focuses on “escalation in therapy” rather than acute management of vision loss; some may argue that immediate increase to high-dose prednisone (or IV methylprednisolone) is required. However, within the frame of chronic management/relapse with large-vessel involvement, tocilizumab is the clearly superior steroid-sparing escalation over re-escalating prednisone or adding methotrexate.\\nMain medical accuracy issue(s): Minor—real-world acute vision loss requires urgent high-dose steroids, but the stem seems to target disease-modifying escalation.\\nMinimal fix: Clarify in the stem that the patient has already been re-treated acutely with high-dose steroids and now requires a steroid-sparing escalation for relapsing, large-vessel GCA.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Known giant cell arteritis; currently on prednisone taper; new jaw claudication and vision loss = active, vision-threatening relapse; ESR 80 mm/hr; negative temporal artery biopsy (does not rule out GCA); CTA with aortic arch involvement = large-vessel GCA; question asks for escalation of therapy.\nTocilizumab is guideline-supported for refractory/relapsing and/or large-vessel GCA and is superior to methotrexate as a steroid-sparing agent. Among options, it is the best escalation beyond glucocorticoids.\nMain logical issue(s): The question focuses on “escalation in therapy” rather than acute management of vision loss; some may argue that immediate increase to high-dose prednisone (or IV methylprednisolone) is required. However, within the frame of chronic management/relapse with large-vessel involvement, tocilizumab is the clearly superior steroid-sparing escalation over re-escalating prednisone or adding methotrexate.\nMain medical accuracy issue(s): Minor—real-world acute vision loss requires urgent high-dose steroids, but the stem seems to target disease-modifying escalation.\nMinimal fix: Clarify in the stem that the patient has already been re-treated acutely with high-dose steroids and now requires a steroid-sparing escalation for relapsing, large-vessel GCA.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}]